JSR to Acquire Selexis and Combine Cell Line Specialist with CDMO KBI Biopharma
genengnews | June 14, 2017
JSR Life Sciences is to acquire mammalian cell-line development specialist Selexis, and integrate the Switzerland-based company with KBI Biopharma, the U.S.-based biopharma contract development and manufacturing organization (CDMO) that Japan-based JSR acquired in 2015.